Abstract
Neuroblastoma (NB) is a rapidly growing, well-vascularized childhood cancer that often presents with metastases. The overall five-year survival in NB is approximately 45% despite multimodality treatment, and therefore there is a clinical need for new therapeutic strategies. NB frequently overexpresses the angiogenic factor VEGF (vascular endothelial growth factor). The aim of this study was to investigate the effect of bevacizumab (Avastin®, Genentech/Roche), a humanized anti-VEGF-A antibody, on NB growth in three different xenograft models, chosen to resemble high-risk NB. The human NB cell lines SK-N-AS, IMR-32 and SH-SY5Y, which are poorly differentiated and overexpress VEGF-A, were injected s.c. in immunodeficient mice. Bevacizumab was given intraperitoneally twice weekly at 5 mg/kg body weight, starting at a tumor volume of 0.3 mL. Bevacizumab significantly (p < 0.01–0.05) reduced NB growth in vivo without toxicity by causing a 30–63% reduction of angiogenesis, but had no effect on NB cell survival in vitro. Serum concentrations of VEGF-A increased two- to six-fold during bevacizumab therapy which did not result in faster tumor growth compared with control animals. Based on our experimental data we suggest consideration of bevacizumab in treatment of high-risk NB that does not respond to conventional therapy and that overexpresses VEGF.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- BW:
-
body weight
- CgA:
-
chromogranin A
- FMCA:
-
fluorescent microculture cytotoxicity assay
- NB:
-
neuroblastoma
- RT:
-
room temperature
- TH:
-
tyrosine hydroxylase
References
Schwab M, Westermann F, Hero B, Berthold F 2003 Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4: 472–480
Folkman J 1971 Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186
Meitar D, Crawford SE, Rademaker AW, Cohn SL 1996 Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14: 405–414
Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, Aharinejad S 2002 Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg 37: 582–587
Komuro H, Kaneko S, Kaneko M, Nakanishi Y 2001 Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127: 739–743
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F 2005 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502–3508
Van Roy N, Jauch A, Van Gele M, Laureys G, Versteeg R, De Paepe A, Cremer T, Speleman F 1997 Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. Cancer Genet Cytogenet 97: 135–142
Zaizen Y, Taniguchi S, Suita S 1998 The role of cellular motility in the invasion of human neuroblastoma cells with or without N-myc amplification and expression. J Pediatr Surg 33: 1765–1770
Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS 1978 Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751–3757
Backman U, Christofferson R 2005 The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 57: 690–695
Qi JH, Matsumoto T, Huang K, Olausson K, Christofferson R, Claesson-Welsh L 1999 Phosphoinositide 3 kinase is critical for survival, mitogenesis and migration but not for differentiation of endothelial cells. Angiogenesis 3: 371–380
Larsson R, Kristensen J, Sandberg C, Nygren P 1992 Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177–185
Svensson A, Backman U, Jonsson E, Larsson R, Christofferson R 2002 CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr Res 51: 607–611
Wassberg E, Hedborg F, Skoldenberg E, Stridsberg M, Christofferson R 1999 Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol 154: 395–403
Christofferson R, Claesson-Welsh L, Muhr C 2002 [Anti-angiogenic drugs probable complement in cancer therapy]. Lakartidningen 99: 4138–4139: 4142-4138
Backman U, Svensson A, Christofferson R 2002 Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 5: 267–274
Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N 2000 Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253–6258
Kim E, Moore J, Huang J, Soffer S, Manley CA, O'Toole K, Middlesworth W, Stolar CJ, Kandel JJ, Yamashiro DJ 2001 All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg 36: 287–290
Gerber HP, Ferrara N 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671–680
Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850
Hsei V, Deguzman GG, Nixon A, Gaudreault J 2002 Complexation of VEGF with bevaczumab decreases VEGF clearance in rats. Pharm Res 19: 1753–1756
Semenza GL 2003 Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721–732
Sweeney CJ, Miller KD, Sledge GW Jr 2003 Resistance in the anti-angiogenic era: nay-saying or a word of caution?. Trends Mol Med 9: 24–29
Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G 1996 The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843–1849
Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F 1999 Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94: 4143–4155
Clements MK, Jones CB, Cumming M, Daoud SS 1999 Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 44: 411–416
Kerbel RS, Viloria-Petit A, Klement G, Rak J 2000 ‘Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36: 1248–1257
Jain RK 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62
Jain RK, Duda DG, Clark JW, Loeffler JS 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24–40
Jain RK 2003 Molecular regulation of vessel maturation. Nat Med 9: 685–693
Acknowledgements
Barbro Einarsson provided excellent technical assistance. Bevacizumab was provided by Genentech Inc (South San Francisco, CA). Serum VEGF analyses were kindly performed by Professor Anders Larsson at the Department of Clinical Chemistry at Akademiska Hospital, Uppsala.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from the Swedish Cancer Society and the Children´s Cancer Foundation of Sweden.
Rights and permissions
About this article
Cite this article
Segerström, L., Fuchs, D., Bäckman, U. et al. The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts. Pediatr Res 60, 576–581 (2006). https://doi.org/10.1203/01.pdr.0000242494.94000.52
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.pdr.0000242494.94000.52
This article is cited by
-
Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement
Journal of Thrombosis and Thrombolysis (2022)
-
Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro
Odontology (2022)
-
Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy
Bulletin of Mathematical Biology (2018)
-
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma
Cancer Immunology, Immunotherapy (2017)
-
Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child
Eye (2015)
